Genomic approach towards personalized anticancer drug therapy

Pharmacogenomics

Volumn 13, Issue 2, 2012, Pages 191-199

  Midorikawa, Yutaka ^a,b   Tsuji, Shingo ^a   Takayama, Tadatoshi ^b   Aburatani, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

anticancer therapy; ensemble method; expression array; machine learning algorithm; personalized therapy; predictor genes

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; VINCRISTINE;

AMZ2P1 GENE; AP3M2 GENE; APPBP2 GENE; BAYESIAN LEARNING; BPTF GENE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CEP290 GENE; CLASSIFICATION ALGORITHM; COLORECTAL CANCER; CSPP1 GENE; DRUG EFFICACY; DRUG SENSITIVITY; EIF1 GENE; ESOPHAGUS CANCER; FAM73A GENE; GENE EXPRESSION; GENOMICS; HUMAN; K NEAREST NEIGHBOR; KIDNEY CANCER; LOGISTIC REGRESSION ANALYSIS; MBTD1 GENE; MICROARRAY ANALYSIS; NMT1 GENE; NPEPPS GENE; OVARY CANCER; PREDICTIVE VALUE; PROGNOSIS; RANDOM FOREST; REGRESSION ANALYSIS; REVIEW; RNF141 GENE; SMURF2 GENE; SRGAP1 GENE; SUPPORT VECTOR MACHINE; TUMOR GENE;

ALGORITHMS; ARTIFICIAL INTELLIGENCE; DRUG RESISTANCE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; INDIVIDUALIZED MEDICINE; MICROARRAY ANALYSIS; MODELS, THEORETICAL; NEOPLASMS;

EID: 84855921970     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.157     Document Type: Review

References (35)

1. Simon R. The use of genomics in clinical trial design. Clin. Cancer Res. 14(19), 5984-5993 (2008).
2. Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26(16), 2690-2698 (2008).
3. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl Acad. Sci. USA 107(20), 9287-9292 (2010).
4. Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Update 13(3), 57-66 (2010).
5. Schwarz DF, Szymczak S, Ziegler A, Konig IR. Evaluation of single-nucleotide polymorphism imputation using random forests. BMC Proc. 3(Suppl. 7), S65 (2009).
6. Van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187), 564-570 (2008).
7. Dressman HK, Hans C, Bild A et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin. Cancer Res. 12(3 Pt 1), 819-826 (2006). (Pubitemid 43259863)
8. Lin Y, Lin S, Watson M et al. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 123(3), 691-699 (2010).
9. Parissenti AM, Hembruff SL, Villeneuve DJ, Veitch Z, Guo B, Eng J. Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. Anticancer Drugs 18(5), 499-523 (2007). (Pubitemid 46597406)
10. Kim BK, Lee JW, Park PJ et al. The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 11(2), R22 (2009).
11. Statnikov A, Wang L, Aliferis CF. A comprehensive comparison of random forests and support vector machines for microarray-based cancer classification. BMC Bioinformatics 9, 319 (2008).
12. Del Rio M, Molina F, Bascoul-Mollevi C et al. Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J. Clin. Oncol. 25(7), 773-780 (2007). (Pubitemid 350002876)
13. Dressman HK, Berchuck A, Chan G et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol. 25(5), 517-525 (2007). (Pubitemid 350002958)
14. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J. Clin. Oncol. 24(26), 4236-4244 (2006). (Pubitemid 46630780)
15. Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin. Cancer Res. 13(4), 1198-1207 (2007). (Pubitemid 46424061)
16. Hayes DN, Monti S, Parmigiani G et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J. Clin. Oncol. 24(31), 5079-5090 (2006). (Pubitemid 46631412)
17. Tebbit CL, Zhai J, Untch BR et al. Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res. Treat. 118(3), 635-643 (2009).
18. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439(7074), 353-357 (2006). (Pubitemid 43128862)
19. Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 12(11), 1294-1300 (2006). (Pubitemid 44706932)
20. Williams PD, Cheon S, Havaleshko DM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 69(21), 8302-8309 (2009).
21. Ioannidis JP, Allison DB, Ball CA et al. Repeatability of published microarray gene expression analyses. Nat. Genet. 41(2), 149-155 (2009).
22. Baggerly KA, Coombes KR. What information should be required to support clinical 'omics' publications? Clin. Chem. doi:10.1373/clinchem.2010.158618 (2011) (Epub ahead of print).
23. Borst P, Wessels L. Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 9(24), 4836-4840 (2010).
24. Lee JK, Coutant C, Kim YC et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin. Cancer Res. 16(2), 711-718 (2010).
25. Bonnefoi H, Potti A, Delorenzi M et al. Retraction-validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 12(2), 116 (2011).
26. Saeys Y, Inza I, Larranaga P. A review of feature selection techniques in bioinformatics. Bioinformatics 23(19), 2507-2517 (2007). (Pubitemid 350048351)
27. Talby L, Chambost H, Roubaud MC et al. The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes. Leuk. Res. 30(6), 665-676 (2006).
28. Duong C, Greenawalt DM, Kowalczyk A et al. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann. Surg. Oncol. 14(12), 3602-3609 (2007). (Pubitemid 350160118)
29. Huang CC, Gadd S, Breslow N et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group. Clin. Cancer Res. 15(5), 1770-1778 (2009).
30. Tsuji S, Midorikawa Y, Takahashi T et al. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br. J. Cancer doi:10.1038/bjc.2011.505 (2011) (Epub ahead of print).
31. Pengyi Y, Yang YH, Zhou BB, Zomaya AY, A review of ensemble methods in bioinformatics. Curr. Bioinformatics 5(4), 296-308 (2010).
32. Diaz-Uriarte R, Alvarez De Andres S. Gene selection and classification of microarray data using random forest. BMC Bioinformatics 7, 3 (2006).
33. Thuerigen O, Schneeweiss A, Toedt G et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 24(12), 1839-1845 (2006). (Pubitemid 46638981)
34. Pers TH, Albrechtsen A, Holst C, Sorensen TI, Gerds TA. The validation and assessment of machine-learning: a game of prediction from high-dimensional data. PLoS ONE 4(8), e6287 (2009).
35. Shi L, Campbell G, Jones WD et al. The MicroArray Quality Control (MAQC) II study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol. 28(8), 827-838 (2010).